Despite the optimism surrounding the over-the-counter (OTC) availability of Narcan, a lifesaving drug for opioid overdoses, acquiring it in the United States isn’t always straightforward. Released to retail in September, following the FDA’s approval in March 2023, Narcan was envisioned as an easily accessible antidote amidst the escalating opioid crisis, particularly with the rise in fentanyl-related deaths.
However, a survey conducted by NBC News, covering 64 stores in 15 states plus Washington, D.C., revealed inconsistencies in Narcan’s availability. While the product was found in various locations within the stores, including locked cases and high shelves, it wasn’t uniformly stocked in all expected outlets. Major drugstores and pharmacies generally carried Narcan, but it was notably absent in convenience stores and gas stations.
Dr. Maryam Jowza from UNC School of Medicine and Jacob Abraham from Mineral Springs Pharmacy shared insights on the missed opportunities and challenges in making Narcan more widely available. Alicia House from Steve Rummler HOPE Network and Dr. Steven Maher from Mayo Clinic emphasized the urgency of having Narcan readily available, given the rapid progression of opioid overdoses.
Despite the distribution of over 20 million doses in 2023 by Emergent BioSolutions, the manufacturer of Narcan, its impact on the opioid crisis remains to be fully assessed. The cost remains a significant barrier, with most stores pricing a two-dose pack around $45, making it inaccessible for many who need it most.
Experts like Dennis Cauchon from Harm Reduction Ohio and Dr. Scott Hadland from Mass General for Children highlight the importance of broader accessibility and lower pricing for Narcan to truly make a difference in combating opioid overdoses. The issue of stigma in purchasing Narcan and the need for more consistent and affordable access are also central concerns in maximizing the drug’s potential impact.